International Stem Cell (ISCO) EBIT Margin (2010 - 2026)
International Stem Cell (ISCO) posted quarterly EBIT Margin of 14.52% for Q4 2025, down 1661.0% year-over-year from 0.93% in Q4 2024, and down 466.04% quarter-over-quarter from 3.97% in Q3 2025.
International Stem Cell (ISCO) EBIT Margin (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported EBIT Margin for 16 consecutive years, with 14.52% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBIT Margin fell 1661.0% year-over-year to 14.52%; the TTM figure through Dec 2025 stood at 2.93% (down 219.0% YoY), while the FY2025 annual figure was 2.93%, down 219.0% from the prior year.
- EBIT Margin slipped to 14.52% in Q4 2025 per ISCO's latest filing, from 3.97% in the prior quarter.
- Across five years, EBIT Margin topped out at 6.82% in Q2 2025 and bottomed at 34.2% in Q1 2021.
- Historically, EBIT Margin has averaged 8.65% across 5 years, with a median of 6.37% in 2023.
- Annual changes were most pronounced in 2022 — EBIT Margin jumped 3544 bps — and 2023, when it tumbled 2496 bps.
- International Stem Cell's EBIT Margin stood at 17.53% in 2021, then soared by 114 bps to 2.51% in 2022, then slumped by 994 bps to 22.45% in 2023, then jumped by 109 bps to 2.09% in 2024, then slumped by 797 bps to 14.52% in 2025.
- Business Quant data shows ISCO's EBIT Margin at 14.52% in Q4 2025, 3.97% in Q3 2025, and 6.82% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | -1.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.31% |
| Dec 31, 2025 | -14.52% |
| Sep 30, 2025 | 3.97% |
| Jun 30, 2025 | 6.82% |
| Mar 31, 2025 | -10.10% |
| Dec 31, 2024 | 2.09% |
| Sep 30, 2024 | -4.13% |
| Jun 30, 2024 | 6.39% |
| Mar 31, 2024 | -8.36% |
| Dec 31, 2023 | -22.45% |
| Sep 30, 2023 | -4.92% |
| Jun 30, 2023 | -7.82% |
| Mar 31, 2023 | 0.10% |
| Dec 31, 2022 | 2.51% |
| Sep 30, 2022 | -17.62% |
| Jun 30, 2022 | 1.53% |
| Mar 31, 2022 | 1.24% |
| Dec 31, 2021 | -17.53% |
| Sep 30, 2021 | -33.82% |
| Jun 30, 2021 | -22.15% |